Dantron

DB04816ApprovedWithdrawnSmall molecule

Dantron is a drug used to relieve acute and chronic inflammation of the oral cavity and oropharynx. Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

Chemical structure of Dantron
Mechanism
Curator reviewed
Formula / weight
C14H8O4 · 240.2109 g/mol (avg)
First approval
Canada, 1993
Also known as
Chrysazin · Danthron

Resolves to

Compound
UNIIZ4XE6IBF3VCAS117-10-2ChEMBLCHEMBL53418ChEBI3682PubChem2950KEGGD07107
Clinical / RWD
RxNorm22293ATCA06AB03ATCA06AB53ATCA06AG03PharmGKBPA449206
Structure
InChIKeyQBPFLULOKWLNNW-UHFFFAOYSA-NSMILESOC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O
Targets
P19793RXRA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
400Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
4Marketed productsAcross 2 countries and 3 labellers
Sign in
3ATC codesIncluding every combination product, plus 11 drug categories
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Dantron, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In